Leveraging existing data to contextualize phase II clinical trial findings in oncology

HER2, phase II trials, oncology, iDFS, EBC, early stage breast cancer

In the USA, over 250,000 women are diagnosed with early-stage breast cancer (EBC) yearly, with up to 30% having HER2 amplification. The standard care for HER2-positive EBC involves chemotherapy plus HER2-directed therapy for one year. The phase II Adjuvant Paclitaxel and Trastuzumab (APT) tr…

Sep 21^st • 3 mins read